Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € ↓ -1,30 (-0,35%)
2026-06-03
AKTIENPREIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionPrudential Financial Inc
Latest Disclosed Ownership7,014,275 shares
Ownership 2.90%
Prudential Financial Inc ownership in 1VRTX / Vertex Pharmaceuticals Incorporated

2015-02-02 - Prudential Financial Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 7,014,275 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX). This represents 2.9 percent ownership of the company.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2015-02-02 2015-02-02 13G/A 7,014,275 2.90
2014-01-29 2014-01-29 13G/A 13,762,985 5.90
2013-02-11 2013-02-11 13G/A 17,993,103 8.30
2012-02-14 2012-02-14 13G 10,731,780 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 131,560 -3,059 -2.27 58,747 -3.74 0.0407
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 134,619 -91,195 -40.39 61,031 -30.99 0.0737
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 225,814 45,578 25.29 88,438 10.21 0.1051
2025-08-12 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 180,236 11,381 6.74 80,241 -1.98 0.1037
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 168,855 717 0.43 81,864 20.91 0.1166
2025-02-11 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 168,138 -42,095 -20.02 67,709 -30.75 0.0928
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 210,233 -79,409 -27.42 97,775 -27.98 0.1378
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 289,642 34,181 13.38 135,761 27.13 0.2038
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 255,461 4,642 1.85 106,785 7.18 0.1504
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 250,819 -53,122 -17.48 99,631 -5.92 0.1505
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 303,941 -170,512 -35.94 105,905 -36.57 0.1662
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 474,453 -59,395 -11.13 166,965 -0.73 0.2431
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 533,848 -146,638 -21.55 168,200 -14.41 0.2634
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 680,486 -38,436 -5.35 196,511 -5.63 0.3312
2022-11-04 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 718,922 13,296 1.88 208,225 4.74 0.3530
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 705,626 -43,229 -5.77 198,809 1.73 0.3154
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 748,855 88,350 13.38 195,428 34.93 0.2597
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 660,505 49,727 8.14 144,834 26.95 0.1800
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 610,778 177,000 40.80 114,083 30.44 0.1592
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 433,778 140,680 48.00 87,463 38.87 0.1203
2021-05-12 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 293,098 -198,252 -40.35 62,983 -45.76 0.0944
2021-08-16 2020-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 0236 92532F100 491,350 485,893 8,904.03 116,126 7,719.93 0.1952
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 491,350 485,893 116,126 0.1952
2021-08-05 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,457 2,050 60.17 1,485 50.15 0.2146
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 503,425 500,018 136,992 0.2584
2021-08-05 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 0290 92532F100 3,407 886 35.14 989 64.83 0.1831
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 715,980 713,459 207,857 0.4002
2021-08-05 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 0237 92532F100 2,521 512 25.49 600 36.36 0.1558
2020-05-12 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 745,359 743,350 177,359 0.3929
2021-08-05 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 0218 92532F100 2,009 835 71.12 440 121.11 0.1147
2020-02-11 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 619,645 618,471 135,672 0.2010
2021-08-05 2019-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 0169 92532F100 1,174 498 73.67 199 60.48 0.0650
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 695,960 695,284 117,910 0.1870
2021-08-05 2019-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 676 246 57.21 124 56.96 0.0431
2019-08-08 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 636,020 635,590 116,633 0.1817
2021-08-05 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 430 189 78.42 79 97.50 0.0335
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 524,699 524,458 96,519 0.1607
2021-08-05 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 241 89 58.55 40 37.93 0.0324
2019-02-07 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 328,127 -577,248 54,374 0.0955
2021-09-01 2018-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 0192 92532F100 152 47 44.76 29 61.11 0.0466
2018-11-07 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 905,375 905,270 174,502 0.2571
2021-09-01 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 105 -279,220 -99.96 18 -99.96 0.0645
2018-08-13 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 311,755 32,430 52,986 0.0792
2018-05-04 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 279,325 -67,930 -19.56 45,524 -12.52 0.0694
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 347,255 670 0.19 52,040 -1.24 0.0709
2017-11-02 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 346,585 -98,140 -22.07 52,695 -8.06 0.0871
2017-08-07 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 444,725 50,350 12.77 57,312 32.90 0.0853
2017-05-10 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 394,375 -158,130 -28.62 43,125 5.95 0.0672
2017-02-07 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 552,505 -73,980 -11.81 40,704 -25.50 0.0655
2016-11-04 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 626,485 106,808 20.55 54,635 22.22 0.0902
2016-08-09 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 519,677 23,460 4.73 44,703 13.33 0.0752
2016-05-09 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 496,217 185,800 59.85 39,445 0.99 0.0706
2016-02-12 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 310,417 7,670 2.53 39,060 23.89 0.0707
2015-11-10 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 302,747 -9,090 -2.91 31,528 -18.12 0.0622
2015-08-06 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 311,837 -1,300 -0.42 38,506 4.24 0.0684
2015-05-01 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 313,137 4,290 1.39 36,941 0.68 0.0640
2015-02-06 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 308,847 -5,780 -1.84 36,691 3.84 0.0665
2014-11-12 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 314,627 -30,537 -8.85 35,335 8.12 0.0665
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 345,164 15,757 4.78 32,680 40.28 0.0576
2014-05-14 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 329,407 41,300 14.33 23,296 8.83 0.0434
2014-02-11 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 288,107 -196,800 -40.59 21,406 -41.78 0.0425
2013-11-07 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 484,907 186,447 62.47 36,766 54.23 0.0782
2013-08-07 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 298,460 298,460 23,838 0.0528
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.